Clinical outcomes of second-line treatment following first-line VEGFR-TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti-PD-1 antibody

Cancer Commun (Lond). 2021 Aug 7. doi: 10.1002/cac2.12206. Online ahead of print.
No abstract available

Publication types

  • Letter